When patients in Pocatello and Southeast Idaho come to our practice after years of inadequate relief from standard antidepressants, they often arrive having done significant research. Increasingly, that research leads them to a specific question:

Should I try IV ketamine or Spravato?

It is a genuinely important question, and the honest answer is that neither is universally better. They are related compounds with distinct formulations, delivery mechanisms, regulatory histories, and practical considerations. The right choice depends on your clinical situation, medical history, insurance coverage, and treatment goals.

This guide gives you the information you need to have that conversation intelligently with your provider.

Both IV ketamine and intranasal esketamine (brand name: Spravato) are NMDA receptor antagonists that produce antidepressant effects through the glutamate system — a mechanism fundamentally different from SSRIs, SNRIs, and other conventional antidepressants. Both:

• Produce rapid antidepressant effects, often within hours to days
• Require administration in a monitored clinical setting
• Cause transient dissociative and perceptual effects during treatment
• Are used specifically for patients who have not responded adequately to standard antidepressants
• Represent some of the most significant advances in depression treatment in decades

The molecular relationship: esketamine is the S-enantiomer of ketamine. Racemic ketamine (the standard compound) consists of two mirror-image molecules — the S-enantiomer (esketamine) and the R-enantiomer (arketamine). Esketamine is approximately twice as potent at NMDA receptors as the racemic mixture.

Intravenous ketamine has been studied in psychiatric applications since the early 2000s. The 2006 Zarate et al. trial demonstrated striking rapid antidepressant effects within 110 minutes of a single infusion in TRD patients — a finding that fundamentally changed the field's understanding of what antidepressant treatment could look like.

By now, IV ketamine has been studied in hundreds of clinical trials. The evidence base is robust: response rates of 50–70% in TRD patients, with effects often beginning within hours.

Delivery and Protocol:

• Administered intravenously over 40–60 minutes at sub-anesthetic dose (typically 0.5 mg/kg, adjusted individually)
• Standard induction series: 6 infusions over 2–3 weeks
• Maintenance infusions at individualized intervals thereafter
• Requires IV access, medical monitoring of vital signs

Regulatory Status: IV ketamine is not specifically FDA-approved for depression or TRD. It is used off-label, legally and widely, based on the extensive evidence base. This means insurance coverage is extremely limited; most patients pay out-of-pocket.

Spravato (esketamine, nasal spray) received FDA approval in March 2019 for treatment-resistant depression, making it the first new antidepressant mechanism approved in decades and the first treatment with a specific TRD indication. In August 2020, a second indication was approved: major depressive disorder with acute suicidal ideation or behavior (MDSI).

The approval was based on a series of randomized, placebo-controlled trials in the TRANSFORM and SUSTAIN programs, demonstrating significant reduction in depression scores versus placebo when added to a newly initiated oral antidepressant.

Delivery and Protocol:

• Self-administered nasal spray (56 mg or 84 mg dose)
• Administered in a certified healthcare setting (REMS program) — patient cannot take home
• Monitoring for at least 2 hours after each dose
• Induction: Twice weekly for 4 weeks
• Maintenance: Weekly for weeks 5–8; then every 1–2 weeks thereafter
• Must be used in conjunction with an oral antidepressant per FDA labeling

Regulatory Status: FDA-approved specifically for TRD and MDSI. This distinction matters for insurance coverage — major insurers have developed coverage policies for Spravato, though prior authorization requirements remain stringent.

Consider IV ketamine if:

• You have limited or no insurance coverage for Spravato and can pay out-of-pocket
• You want the most precisely titrated, individually customized dosing
• You prefer a treatment with the longest clinical history and largest evidence base
• Your provider has experience and infrastructure for IV ketamine administration

Consider Spravato if:

• You have insurance coverage that includes Spravato after prior authorization
• You cannot or prefer not to have intravenous access
• The FDA-approved status provides additional reassurance
• You have documented TRD and are willing to continue an oral antidepressant concurrently

In practice, many patients and providers choose based on insurance coverage first, and then refine based on clinical response. Patients who don't respond adequately to one formulation sometimes respond to the other.

Navigating insurance for either option requires documentation. For Spravato specifically, major insurers typically require:

• Formal diagnosis of treatment-resistant depression
• Documentation of at least 2 adequate antidepressant trials
• Prior authorization from the treating provider
• Concurrent oral antidepressant prescription

Our practice assists patients in preparing documentation for prior authorization and works with patients on financial planning for IV ketamine when insurance coverage is unavailable.

Can I switch from one to the other if my first choice doesn't work? Yes. Non-response to one formulation does not preclude response to the other. We have had patients who were partial responders to IV ketamine achieve fuller response with Spravato, and vice versa.

Which has a better side effect profile? Both produce similar dissociative and hemodynamic effects. Spravato adds potential nasal irritation or discomfort. Neither has a clearly superior side effect profile overall.

Does Spravato really require a 2-hour monitoring period every session? Yes. This is an FDA requirement under the REMS program — it cannot be waived. Sessions must be conducted in a certified setting with post-dose monitoring.

How do I get started with either option in Pocatello? Contact Roth Family Medicine and Mental Health for a comprehensive TRD evaluation. We'll review your history, determine eligibility, assess which option fits your clinical situation and insurance status, and build a complete treatment plan.

1. Zarate CA Jr, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.
2. Daly EJ, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression. JAMA Psychiatry. 2019;76(9):893–903.
3. Murrough JW, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression. Am J Psychiatry. 2013;170(10):1134–1142.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before pursuing any treatment.

Kyle Roth, FNP-BC, APRN, MSN, MHA | Roth Family Medicine and Mental Health | Pocatello, Idaho | (208)-904-4705 | www.rothfamilymed.com